Cooperative Signaling Through the STAT3 and NF-kB Pathways in Subtypes of Diffuse Large B Cell Lymphoma
暂无分享,去创建一个
L. Staudt | R. Davis | A. Rosenwald | R. Gascoyne | P. Farinha | G. Lenz | L. Lam | George E. Wright | L. Dang | John W. Chan
[1] L. Staudt,et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma , 2007, Leukemia.
[2] D. Gary Gilliland,et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders , 2007, Nature Reviews Cancer.
[3] Eric S. Lander,et al. Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene , 2007, Cell.
[4] G. Stark,et al. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.
[5] S. Cory,et al. The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.
[6] Zhizhuang Joe Zhao,et al. Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth* , 2006, Journal of Biological Chemistry.
[7] Hua Yu,et al. Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.
[8] John Calvin Reed,et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.
[9] C. Scott,et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.
[10] V. Sasseville,et al. Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. , 2006, Blood.
[11] W. Chan,et al. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. , 2006, Blood.
[12] Liming Yang,et al. A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.
[13] L. Staudt,et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology , 2006, Immunological reviews.
[14] L. Staudt,et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Stefano Monti,et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma , 2006, The Journal of experimental medicine.
[16] Hua Yu,et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.
[17] E. Hurt,et al. The role of IL-6 and STAT3 in inflammation and cancer. , 2005, European journal of cancer.
[18] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[19] Eric B Haura,et al. Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer , 2005, Nature Clinical Practice Oncology.
[20] D. Levy,et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. , 2005, Cancer research.
[21] L. Staudt,et al. Small Molecule Inhibitors of IKB Kinase Are Selectively Toxic for Subgroups of Diffuse Large B-Cell Lymphoma Defined by Gene Expression Profiling , 2005 .
[22] T. Kishimoto. Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.
[23] L. Staudt,et al. The biology of human lymphoid malignancies revealed by gene expression profiling. , 2005, Advances in immunology.
[24] S. Korsmeyer,et al. Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.
[25] G. Marti,et al. Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma , 2004, Leukemia.
[26] P. Auron,et al. Interleukin 1 Activates STAT3/Nuclear Factor-κB Cross-talk via a Unique TRAF6- and p65-dependent Mechanism* , 2004, Journal of Biological Chemistry.
[27] Hua Yu,et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.
[28] Nicola Gebbia,et al. STAT proteins: From normal control of cellular events to tumorigenesis , 2003, Journal of cellular physiology.
[29] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[30] K. Ohta,et al. Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. , 2003, Blood.
[31] K. Rajewsky,et al. IκB Kinase Signaling Is Essential for Maintenance of Mature B Cells , 2002, The Journal of experimental medicine.
[32] Peter J. Murray,et al. Shaping Gene Expression in Activated and Resting Primary Macrophages by IL-101 , 2002, The Journal of Immunology.
[33] C. Ball,et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.
[34] N. Liverton,et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. , 2002, Bioorganic & medicinal chemistry letters.
[35] R. Gascoyne,et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. , 2002, Blood.
[36] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[37] Ulrich Siebenlist,et al. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.
[38] J. Miyazaki,et al. Tissue-Specific Autoregulation of thestat3 Gene and Its Role in Interleukin-6-Induced Survival Signals in T Cells , 2001, Molecular and Cellular Biology.
[39] Andreas Rosenwald,et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol , 2001, Genome Biology.
[40] L. Staudt,et al. Signatures of the immune response. , 2001, Immunity.
[41] R. Coffman,et al. Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.
[42] Ronald W. Davis,et al. Transcriptional regulation and function during the human cell cycle , 2001, Nature Genetics.
[43] L. Staudt,et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. , 2000, Immunity.
[44] Roy Garcia,et al. STATs in oncogenesis , 2000, Oncogene.
[45] J. Darnell,et al. The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.
[46] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[47] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[48] D. Hilton,et al. The SOCS proteins: a new family of negative regulators of signal transduction , 1998, Journal of leukocyte biology.
[49] Warren S. Alexander,et al. A family of cytokine-inducible inhibitors of signalling , 1997, Nature.
[50] J. Blay,et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. , 1996, Cancer research.
[51] S. Akira,et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway , 1994, Cell.
[52] K. Anderson,et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. , 1993, Blood.
[53] J. Banchereau,et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[54] X. H. Wang,et al. A possible autocrine role for interleukin-6 in two lymphoma cell lines. , 1989, Blood.
[55] H. Asaoku,et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.
[56] T. Taniguchi,et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.
[57] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.